Wedbush downgraded Tourmaline Bio (TRML) to Neutral from Outperform with an unchanged $48 price target after the company entered into a merger agreement with Novartis (NVS), pursuant to which Novartis will acquire Tourmaline for $48.00 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Novartis Seals $1.4B Deal with Tourmaline Bio (TRML) to Bolster Heart Disease Portfolio
- Tourmaline Bio Merges with Novartis for $1.4 Billion
- Tourmaline Bio to be acquired by Novartis for $48.00 per share in cash
- Tourmaline Bio’s Promising Drug Developments and Strategic Positioning Make It a Top Pick for 2024
- Tourmaline Bio’s Pacibekitug: A Promising Contender in ASCVD Treatment with Undervalued Potential